Lokelma Maintenance Dosing for Chronic Hyperkalemia
For maintenance therapy of chronic hyperkalemia, start Lokelma at 10 g once daily after the initial correction phase, then titrate between 5 g every other day and 15 g daily based on serum potassium levels, with dose adjustments made at weekly intervals or longer. 1
Dosing Algorithm
Standard Maintenance Regimen (Non-Dialysis Patients)
After completing the initial 48-hour correction phase (10 g three times daily), transition to maintenance dosing:
- Starting dose: 10 g once daily 1
- Dose range: 5 g every other day to 15 g daily 1
- Titration intervals: Adjust at 1-week intervals or longer 1
- Titration increments: 5 g adjustments 1
Monitor serum potassium regularly and adjust based on levels:
- If potassium remains elevated: Increase by 5 g increments
- If potassium falls below target range: Decrease dose or discontinue 1
Hemodialysis Patients
For patients on chronic hemodialysis, the approach differs significantly:
- Timing: Administer only on non-dialysis days 1
- Starting dose: 5 g once daily on non-dialysis days 1
- Higher starting dose: Consider 10 g once daily on non-dialysis days if serum potassium >6.5 mEq/L 1
- Dose range: 5 g to 15 g once daily on non-dialysis days 1
- Monitoring: Base adjustments on pre-dialysis potassium after the long interdialytic interval 1
Clinical Evidence Supporting Maintenance Dosing
The HARMONIZE trial demonstrated that once-daily maintenance dosing effectively maintains normokalemia. During the 28-day maintenance phase, mean serum potassium levels were:
- 5 g daily: 4.8 mEq/L
- 10 g daily: 4.5 mEq/L
- 15 g daily: 4.4 mEq/L
- Placebo: 5.1 mEq/L (all doses P<0.001 vs placebo) 2
Long-term data from HARMONIZE-OLE showed sustained efficacy over 11 months, with 93% of patients achieving mean serum potassium ≤5.1 mEq/L across days 8-337 using individualized dosing (mean daily dose 7.2 g) 2, 3
Duration of Therapy
Unless the cause of hyperkalemia is reversible, treatment should be indefinite 4. Patients with chronic conditions like CKD and heart failure face ongoing recurrence risk and require continuous potassium-lowering therapy with periodic assessment of efficacy and adherence 4.
Monitoring Strategy
After achieving normokalemia with a potassium binder, resume guideline-directed monitoring appropriate for underlying conditions rather than intensified hyperkalemia-specific monitoring 4. Standard recommendations include:
- CKD, heart failure, or diabetes: 2-4 times yearly 4
- After RAASi initiation/titration: Within 1-4 weeks 4
- After dose adjustments: Assess potassium after one week 1
Important Considerations
Sodium Content Warning
Each 5 g dose contains approximately 400 mg sodium. Monitor for edema, particularly in patients requiring sodium restriction or prone to fluid overload 1. In clinical trials, edema was generally mild-to-moderate and more common with the 15 g daily dose 2.
Drug Interactions
Administer other oral medications at least 2 hours before or after Lokelma to avoid potential binding interactions 1.
Gastrointestinal Precautions
Avoid use in patients with severe constipation, bowel obstruction, or impaction, as Lokelma has not been studied in these populations and may worsen gastrointestinal conditions 1.
Hypokalemia Risk
While generally low (1% with potassium <3.0 mEq/L, 5% with potassium 3.0-3.4 mEq/L in long-term studies), monitor for hypokalemia and reduce or discontinue if potassium falls below target range 3. Caution is particularly warranted in patients with mild hyperkalemia at baseline, where even maintenance dosing may precipitate hypokalemia 5.
Enabling RAASi Optimization
A critical benefit of maintenance Lokelma therapy is enabling continuation and optimization of renin-angiotensin-aldosterone system inhibitors. In the 12-month open-label study, 87% of baseline RAASi users continued or increased their dose, while only 11% discontinued 3. This is clinically significant given that RAASi discontinuation or down-titration after hyperkalemia events is associated with higher mortality and worse cardiorenal outcomes 4.